Main Menu

SPRUCE Logo

 

A Study within a trial (SWAT) of electronic versus paper-based Patient Reported oUtcomes CollEction

 

Host Trials: PACE-C, PIVOTALboost (pending)

Study Modalities: ePRO (electronic patient reported outcomes), paper PRO (paper patient reported outcomes)

Status: Open for Recruitment

 

Study details

SPRUCE is a partially randomised patient preference study within a trial (SWAT) investigating electronic versus paper PRO collection. As a SWAT, SPRUCE will be run in multiple ICR-CTSU host trials to include participants affected by a range of cancers representative of those in ICR-CTSU’s trial portfolio.

The study will assess if participants complete electronic questionnaires at similar rates to our paper questionnaires and also also investigate whether the type of questionnaire people complete affects their responses.

366 participants will be recruited from host trials. Those who provide written informed consent will be either randomised 1:1 between electronic and paper PRO questionnaire completion or registered for electronic or paper PRO collection if they elect to join the patient preference arm of the study.

 

Further information

Chief Investigator: Dr Lara Phillipps, The Institute of Cancer Research / Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Emma Hall

ePRO Methodology Leads:

Jo Haviland

Rebecca Lewis – Clinical Trials Programme Manager

Trial Management Contact: [email protected]

CPMS: 50553 

Sponsor: The Institute of Cancer Research

 

Publications and presentations

Philipps L, Stiles M, Manning G, Omar A, Lloyd L, Haviland J, Gillman, A, Hall E, Lewis R, A Study within a trial (SWAT) of electronic versus paper-based Patient Reported oUtcomes CollEction, National Cancer Research Institute Cancer Conference, Nov 2021

Philipps L, Haviland J, Gillman, A, Hall E, Lewis R, Study within a trial comparing electronic versus paper patient reported outcome collection. Presented at: Society of Clinical Trials

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.